Privi Speciality Chemicals Limited (BOM:530117)

India · Delayed Price · Currency is INR

3,268.05

+8.15 (0.25%)

At close: Apr 28, 2026

72.56% (1Y)

Market Cap	127.34B
Revenue (ttm)	24.56B
Net Income (ttm)	3.00B
Shares Out	39.06M
EPS (ttm)	76.89
PE Ratio	42.40
Forward PE	34.37
Dividend	5.00 (0.15%)
Ex-Dividend Date	n/a

Volume	2,696
Average Volume	8,051
Open	3,255.35
Previous Close	3,259.90
Day's Range	3,245.80 - 3,287.20
52-Week Range	1,853.60 - 3,433.00
Beta	-0.20
RSI	70.37
Earnings Date	Apr 30, 2026

About BOM:530117

Privi Speciality Chemicals Limited engages in the manufacture, supply, and export of aroma and fragrance chemicals in India, North America, Asia, the Middle East, Africa, Europe, South America, and the United Kingdom. It offers a range of aroma chemicals, including alpha damascone, alpha ionone, alpha terpenyl acetate, amber fleur, amber gamma, beta iso damascol, BI perfumery grade, BI technical grade, carene-60 and carene-90, carvacrol, cedar ketol, citronellal, citronellol, citronellyl acetate, citronellyl nitrile, dipentene, double distilled... [Read more]

Industry Industrial Organic Chemicals

Founded 1985

Employees 672

Stock Exchange Bombay Stock Exchange

Ticker Symbol 530117

Full Company Profile

Financial Performance

In fiscal year 2025, BOM:530117's revenue was 21.01 billion, an increase of 19.91% compared to the previous year's 17.52 billion. Earnings were 1.87 billion, an increase of 97.03%.

Financial Statements

News

Privi Speciality Chemicals Transcript: Q3 25/26

Reported 24% YoY revenue growth and 25%+ EBITDA margins for Q3 and nine months, with strong operational efficiency and robust export demand. Capacity expansion and new product launches are on track, targeting INR 5,000 crore revenue and INR 1,000 crore EBITDA in 3-4 years.

2 months ago - Transcripts

Privi Speciality Chemicals Transcript: Q2 25/26

Record Q2 and H1 FY2026 results with 26% YoY revenue and 59% YoY EBITDA growth, driven by volume and new products. Capacity expansion, robust demand, and state incentives support a strong outlook, with a 3-4 year target of doubling revenue and EBITDA.

6 months ago - Transcripts

Privi Speciality Chemicals Transcript: Q1 25/26

Q1 FY26 saw 22% revenue growth and 45% EBITDA growth, with margins at 24.8%. Capacity expansions, strong ESG performance, and a merger are set to drive 20% annual growth and INR 5,000 crore revenue in 3–5 years. Gross margins and efficiency gains remain robust.

9 months ago - Transcripts

Privi Speciality Chemicals Transcript: Q4 24/25

Record FY25 results with 19% revenue and 37% EBITDA growth, driven by process improvements, new products, and strong export demand. Margins are expected to remain above 20% as capacity expands and value-added products increase. CapEx of INR 250-300 crore planned for further growth.

1 year ago - Transcripts

Privi Speciality Chemicals Transcript: Q3 24/25

Q3 and nine-month results showed strong revenue and margin growth, driven by capacity expansion, improved product mix, and process efficiencies. A robust order book, price increases, and ongoing capex support a positive outlook, with 20% revenue growth targeted for FY26.

1 year ago - Transcripts